Background : Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults accounting for about 80% of adult leukemia cases. In contrast, it accounts for less than 10% of children less than ten years of age. In the last two decades
Search Results
EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019
Alaaeldin Ahmed, Chinmay Jani, Padmanabh Bhatt, Harpreet Singh, Ruchi Jani, Joseph Shalhoub, Dominic Marshall, Prudence Lam, and Justin Salciccioli
HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data
Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Eric Padron, and David Sallman
.1, D46.9, D46.A, and D46.B) from Oct 2015 to Mar 2023. No diagnosis of MDS/acute myeloid leukemia (AML) or use of higher-risk MDS or AML medication before their respective index diagnosis dates were allowed. Lines of treatment were determined by the
CLO23-066: Risk of Secondary Malignancies After Platinum-Based Chemotherapy in Testicular Seminoma Patients: A Population-Based Study
Hiffsa Taj, Ayman Qasrawi, and Zin Myint
myeloid leukemia (SIR 11.86, CI: 5.12–23.38). Conclusions: In our study, patients with seminoma had increased risk of contralateral testis cancers. Patients with stage I who received chemotherapy did not have increased risk of other solid or hematologic
QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment
Shane Burke, Galina Vugman, Noreen McGowan, and Michelle Sharrett
Comprehensive Cancer Network (NCCN) Guidelines recommend treatment patterns based on risk of progression into Acute Myeloid Leukemia (AML). Adherence to these guidelines improves survival rates in patients with MDS. An MDS work-up should include an extensive
Developmental Therapeutics for Myelodysplastic Syndromes
Aung Naing, Lubomir Sokol, and Alan F. List
. 22. Foran J Paquette R Copper M . A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed or are not eligible for conventional chemotherapy [abstract] . Blood 2002 ; 100
Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress
Constantine S. Mitsiades and Kenneth C. Anderson
-sensitive ovarian tumors . Nat Med 2003 ; 9 : 568 - 574 . 54. Melki JR Vincent PC Clark SJ . Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia . Cancer Res 1999 ; 59 : 3730 - 3740 . 55. Hegi ME Liu L Herman JG
Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database
Guru Subramanian Guru Murthy, Aniko Szabo, Laura Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Sameem Abedin, and Ehab Atallah
Background Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) that is characterized by chromosomal translocation t(15;17) with fusion of PML-RARA genes and cell-cycle arrest at the promyelocyte stage. 1 APL
Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies
Sara E. Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke, and Mike G. Martin
urgent leukapheresis, a bone marrow biopsy was performed and a diagnosis of acute myeloid leukemia (AML) was made. He was started on induction chemotherapy with cytarabine, idarubicin, and cladribine (7+3+5). 4 The final bone marrow biopsy revealed high
Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy
Sophia Koo and Lindsey R. Baden
lymphoproliferative disorders . Blood 2002 ; 100 : 3121 – 3127 . 51. Ho AY Pagliuca A Kenyon M . Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia
The NCCN 2019 Annual Congress: Hematologic Malignancies
Robert W. Carlson
neoplasms. Also in the congress, blood cancer experts described updates in treatment strategies for Hodgkin lymphoma, advances in first-line acute myeloid leukemia management, and progress in personalized therapeutic approaches in myelodysplastic syndromes